Section Arrow
Quote
LIXT.NASDAQ
- Lixte Biotechnology Holdings
(Financial Status)
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 1.2501
+0.0301 (+2.47%)
Day High 
1.26 
Prev. Close
1.22 
1-M High
1.4721 
Volume 
6.75K 
Bid
1.2
Ask
1.39
Day Low
1.2144 
Open
1.22 
1-M Low
1.02 
Market Cap 
3.27M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.26 
20-SMA 1.23 
50-SMA 1.76 
52-W High 3.87 
52-W Low 1.02 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.59/--
Enterprise Value
3.27M
Balance Sheet
Book Value Per Share
-1.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. Itfocuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.